Printer Friendly

Bayer initiates Phase III clinical study of Trasylol[R] therapy during primary total hip replacement surgery.

Bayer Pharmaceuticals Corporation has announced the initiation of a Phase III controlled clinical study to evaluate the safety and efficacy of Trasylol[R] (aprotinin injection) in reducing blood loss and the need for transfusion in patients undergoing elective primary total hip replacement surgery.

Trasylol is currently approved for use in more than 60 countries. In the United States, TrasyloI is indicated for prophylactic use to reduce perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass (CPB) in the course of coronary artery bypass graft (CABG) surgery. The drug acts by inhibiting multiple mediators resulting in the attenuation of inflammatory responses, which in CABG surgery translates into reduced bleeding and a decreased need for allogeneic (blood donated from another individual) blood transfusions. The double-blind, placebo-controlled trial has been initiated to assess the drug's hemostatic (blood sparing) effects in primary total hip replacement surgery. Patients undergoing primary total hip replacement surgery lose an average of three units of blood, which often must be replaced by a transfusion.

"Current blood supply shortages and the rising cost of this precious commodity, along with potential health risks associated with transfusions, underscore the need for a therapeutic option in this setting," said Dr. David Nazarian, hip and knee replacement specialist at Pennsylvania Hospital in Philadelphia. "Since Trasylol is widely used as a hemostatic agent in reducing the need for transfusion in CABG surgery, we are investigating its effects in primary total hip replacement where blood loss may result in unnecessary exposure to donor blood."
COPYRIGHT 2005 Advantage Business Media
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Industry News
Publication:Pharmaceutical Processing
Date:May 1, 2005
Words:253
Previous Article:Prana Biotechnology cancels plans for PLACQUE clinical study.
Next Article:FDA to "revisit" intravenous immune globulin clinical trial design.
Topics:

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters